Celldex Therapeutics, Inc

CLDX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CLDX Income Statement
CLDX Balance Sheet
CLDX Cash Flow
Congress Trading

Recent trades of CLDX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CLDX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CLDX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CLDX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CLDX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Treatment of eosinophil or mast cell related disorders May. 21, 2024
  • Patent Title: Anti-kit antibodies and uses thereof Feb. 06, 2024
  • Patent Title: Anti-met antibodies and methods of use thereof Jan. 30, 2024
  • Patent Title: Anti-kit antibodies and uses thereof Jan. 30, 2024
  • Patent Title: Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs Oct. 04, 2022
  • Patent Title: Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs May. 17, 2022
  • Patent Title: Antibodies that bind human cd27 and uses thereof Nov. 23, 2021
  • Patent Title: Anti-alk antibodies and methods for use thereof Aug. 17, 2021
  • Patent Title: Methods of inducing or enhancing an immune response comprising administering agonistic anti-cd40 antibodies Mar. 09, 2021
  • Patent Title: Nucleic acids encoding agonistic antibodies that bind cd40 Dec. 15, 2020
  • Patent Title: Methods of treating by administering anti-kit antibodies Oct. 06, 2020
  • Patent Title: Methods of treating by administering anti-kit antibodies Sep. 22, 2020
  • Patent Title: Treatment of eosinophil or mast cell related disorders Sep. 15, 2020
  • Patent Title: Anti-erbb antibodies and methods of use thereof Aug. 18, 2020
  • Patent Title: Treatment of eosinophil or mast cell related disorders Mar. 26, 2019
  • Patent Title: Polynucleotides encoding anti-kit antibodies Jan. 29, 2019
  • Patent Title: Methods of treating a kit-associated cancer by administering anti-kit antibodies Jan. 22, 2019
  • Patent Title: Treatment of chronic nephropathies using soluble complement receptor type i (scr1) May. 16, 2017
  • Patent Title: Method of improving transplant function using soluble complement receptor type i (scr1) May. 16, 2017
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Apr. 18, 2017
  • Patent Title: Polynucleotides encoding anti-kit antibodies Mar. 28, 2017
  • Patent Title: Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof Feb. 28, 2017
  • Patent Title: Treatment of chronic nephropathies using soluble complement receptor type i (scr1) Mar. 29, 2016
  • Patent Title: Antibody vaccine conjugates and uses therefor Feb. 16, 2016
  • Patent Title: Antibody vaccine conjugates and uses therefor Jan. 26, 2016
  • Patent Title: Antibodies that bind human cd27 and uses thereof Oct. 27, 2015
  • Patent Title: Monoclonal antibodies to dendritic cells Aug. 04, 2015
  • Patent Title: Method of detecting and treating tuberous sclerosis complex associated disorders Jun. 09, 2015
  • Patent Title: Antibodies directed to gpnmb and uses thereof Sep. 30, 2014
  • Patent Title: Treatment for age-related macular degeneration and other diseases of the eye Mar. 04, 2014
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Nov. 19, 2013
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Jan. 29, 2013
  • Patent Title: Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (mcsp) Nov. 27, 2012
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Aug. 07, 2012
  • Patent Title: Method for enhancing t cell reactivity toward tumour antigens Mar. 16, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CLDX in WallStreetBets Daily Discussion

CLDX News

Recent insights relating to CLDX

CNBC Recommendations

Recent picks made for CLDX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CLDX

CLDX Top Shareholders
Shareholder
Shares Held
CLDX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CLDX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CLDX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top